Stem cells and a cure for type 1 diabetes?

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 37, 2009, Pages 15523-15524

  Todd, John A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; NOTE; PANCREAS ISLET; PHENOTYPE; PRIORITY JOURNAL; STEM CELL;

ADULT STEM CELLS; AUTOIMMUNITY; CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 1; HUMANS; PLURIPOTENT STEM CELLS;

EID: 70349461184     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908373106     Document Type: Note

References (17)

1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676. (Pubitemid 44233629)
2. Zhou H, et al. (2009) Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 4:381-384.
3. Dimos JT, et al. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321:1218-1221.
4. Maehr R, et al. (2009) Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci USA 106:15768-15773.
5. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G (2009) Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: A multicenter prospective registration study. Lancet 373:2027-2033.
6. Staeva-Vieira T, Peakman M, von Herrath M (2007) Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 148:17-31. (Pubitemid 46364996)
7. Wentworth JM, Fourlanos S, Harrison LC (2009) Reappraising the stereotypes of diabetes in the modern diabetogenic environment. Nat Rev Endocrinol, 10.1038/nrendo.2009.149.
8. Clayton DG (2009) Prediction and interaction in complex disease genetics: The experience in type 1 diabetes. PLOS Genet 5:c1000540.
9. Sung HH, et al. (2004) Transgenic expression of decoy receptor 3 protect islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice. J Exp Med 199:1143-1151.
10. King MA, et al. (2009) Human peripheral blood leukocyte nonobese diabetic-severe combined immunodeficiency interleukin-2 receptor γ chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 157:104-118.
11. Hayday AC, Peakman M (2008) The habitual, diverse, and surmountable obstacles to human immunology research. Nat Immunol 9:575-580.
12. Davis MM (2008) A prescription for human immunology. Immunity 29:835-838.
13. Rainbow DB, et al. (2008) Commonality in the genetic control of type 1 diabetes in human and NOD mice: Variants of genes in the IL-2 pathway are associated with autoimmune diabetes in both species. Biochem Soc Trans 36:312-315.
14. Dendrou CA, et al. (2009) Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable bioresource. Nat Genet, in press.
15. Roep BO (2007) Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann NY Acad Sci 1103:1-10.
16. Achenbach P, Barker J, Bonifacio E (2008) Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization. Curr Diab Rep 8:87-93.
17. Langer-Gould A, Steinman L (2006) What went wrong in the natalizumab trials? Lancet 367:708-710. (Pubitemid 43326272)